Search

Your search keyword '"Zarif, B"' showing total 21 results
Start Over Author "Zarif, B"
21 results on '"Zarif, B"'

4. PRELIMINARY STUDY OF SG SERAI HOT SPRING, HULU LANGAT, MALAYSIA

Author

Alea Atiqah Bt Mahzan, Anis Syafawanie Bt Ramli, Anis Syafiqah Bt Mohd Abduh, Izulalif B. Izhar, Mohd Zarif B. Mohd Yusof Indirakumar, Amgad Abdelazim Mohamed Salih, Anas Syafiq B. Ahmad Jahri, and Ong Qing Wei

Subjects
Hydrology, Preliminary report, geology, lcsh:TD201-500, Hot spring, Langat basin, lcsh:Water supply for domestic and industrial purposes, Environmental science, Ocean Engineering, water quality, Waste Management and Disposal, Industrial and Manufacturing Engineering, Water Science and Technology
Abstract

The study was conducted to do preliminary review of geology & water quality at Sg Serai hot spring, Hulu Langat, Selangor, Malaysia. Langat River basin can be divided into 3 distinct zones. The first can be referred to as the mountainous zone of the northeast corner of Hulu Langat district. The second zone is the hilly area characterised by gentle slopes spreading widely from north to the east in the middle part of Langat basin. The third zone is a relatively flat alluvial plane located in the southwest of Langat Basin. Water samples, SSP2 and SSW2 are polluted, with an anomalously high reading of fluoride. Fluorosis has been described as an endemic disease of tropical climates, but this is not entirely the case. Waters with high fluoride concentrations occur in large and extensive geographical belts associated with a) sediments of marine origin in mountainous areas, b) volcanic rocks and c) granitic and gneissic rocks; resulting the high concentration of fluoride in water samples.

Published
2017
Full Text
View/download PDF

5. Interventional treatment in diabetics in the era of drug-eluting stents and compliance to the ESC guidelines: lessons learned from the Euro Heart Survey Programme

Author

Onuma Y., Kukreja N., Ramcharitar S., Hochadel M., Gitt A., Serruys P., Marco J., Vahanian A., Weidinger F., Wijns W., Zeymer U., Silber S., Seabra-Gomez R., Eberli F., Manini M., Bramley C., Laforest V., Taylor C., Huber K., Backer G. D., Sirakova V., Cerbak R., Thayssen P., Aziz O. A., Tammam K., Lehto S., Delahaye F., Kobulia B., Cokkinos D., Kremastinos D., Karlocai K., Shelley E., Behar S., Maggioni A., Grabauskiene V., Deckers J., Asmussen I., Stepinska J., Goncalves L., Fonseca C., Mareev V., Vasilijevic Z., Riecansky M. I., Kenda M. F., Lopez-Sendon J. L., Rosengren A., Buser P., Okay T., Sychov O., Schofield P., Gitt A. K., Tavazzi L., Gomes R. S., de la Iglesia J. M., Wallentin L., Kearney P., McGregor K., Simoons M. L., Squibb B. -M., Lilly E., Margaryan K., Khachatryan S., Doerler J., Stocker E. -M., Altenberger I. J., Heigert M., Pichler M., Christ S. G., Glogar H., Lang I., Ingerle S., De Wilde P., de Marneffe M., Vrolix B. M., Dens J., Lierde J. V., De Wagter G. X., Carlier G. M., Weyne G. A., Legrand K. V., Doneux P., Gach O., Davin L., Mievis L. E., Massart P. -E., Holvoet N. G., Giunio L., Glavas D., Vukovic I., Markovic B., Duplancic D., Runjic F., Galic S. E., Mirat J., Kala P., Semenka J., Hlinomaz O., Petrikovits E., Widimsky B. P., Tousek P., Varvarovsky P. I., Cappelen H., Helqvist O. S., Kelbaek H., Jorgensen E., Engstrom T., Saunamaki K., Kastrup J., Clemmensen P., Hansen H., Al Abbadi M., Razek H. A., Aboul el Nasr G., Ragi H., Ibrihim B., Zarif B., el Banhawy N., Sorour K., Meguid M. A., Mahrous A., Al Khashab K. A., Ahmed Abd Elmoniem F., El Emry M., El Naggar A., Saad B. A., Laanmets P., Voitk J., Lutter P., Jarvekulg S., Jalakas M., Reinmets J., Marandi T., Peeba M., Serka T., Syvannne M., Kaihovirta E., Korpilahti H. K., Vaittinen M. -A., Bassand J. -P., Espinosa D. P., Cottin B. Y., Lhuillier I., Buffet P., Lorgis L., Machecourt D. J., Bertrand B., Serrano D., Bonnet G. J. -L., Steg M. P. G., Juliard J. -M., Farnoud R., Delarche P. N., Marco P. J., Petit F., Farah B., Carrie D., Galinier M., Puel J., Cahuzac J., Roncalli J., Tauzin S., Elbaz M., Schachinger V., Gitt F. A., am Rhein Ralf Zahn L., Fraiture B., Haetinger S., Klepzig N. H., Girth E., Hauber A., Firschke O. C., Widmaier J., Hofbauer F., Huttl S., Sechtem P. U., Parade U., Linnartz S. G., Andrianidis S., Tsiavou N., Papaioannou G., Deliargyris E., Attikis M., Alexopoulos D., Davlouros P., Tsikaderis D., Dardas P., Mezilis N., Istvan E., Zoltan B., Turgeman Y., Khaled S., Feldman A., Jafari J., Manevich I., Cafri C., Ilia R., Abu-Ful A., Yaroslavslev S., Wainstain J. M., Rosenchtein G., Sheva B., Krakover R., Yakov B., Halon D., Gruberg L., Markiewicz W., Grenadier E., Boulos M., Roguin A., Kerner A., Amikam S., Ben-Tzvi M., Rezmovitz J., Mosseri H. M., Lotan H., Varshizky B., Nassar H., Daninberg H., Rot D., Vais T., Benhorin J., Keren A., Medina A., Huri Z., Brandis J. S., Schoenmann G., Kornowski N. R., Assali A., Fuch S., Hasdai D., Brosh D., Sela O., Teplitski I., Tikva P., Eisenberg O., Banai S., Finkelstein A., Hasin Y., Aboud M., Nahir M., Qarwani D., Diab G., Meloni L., Lai G., Cadeddu M., Pirisi R., Bonechi F., Nassi F., Nieri M., Taiti A., Naldoni A., Calabro F., Achilli F., Maggiolini S., Piatti L., Tiberti G., Addamiano P., Berti S., Ravani M., Palmieri C., Trianni G., Cardullo S., Cioppa A., Rubino P., Ambrosini V., Salemme L., Sorropago G., Tesorio T., Geraci G., Scalise F., Mazzeti S., Auguadro C., Esposito G., Canali G., Caccia M. E., Ruggieri C., Benedetta B., de Cesare N., De Benedictis M., Coco T., Manzotti S., Fraz O. S., Marraccini P., Danesi A., Ricci R., Ferraironi A., Olivieri E., Chiera A., Garducci S., Grasseli D., McFadden E., Cahill N., Quinn M., Crean P., Caroll E., Foley D., O'Connor S., O'Hanlon R., Lynch B., O'Donnell S., Roy J., O'Brien D., Krastina A., Erglis A., Lawand S., Dorniak W., Klaudel J., Pawlowski K., Trenkner W., Janion M., Sadowski M., Janion-Sadowska A., Skorupa I., Bystryk L., Kern A., Janiak B., Szelemej R., Ruzyllo W., Witkowski A., Deptuch T., Maczynska-Mazuruk R., Budaj A., Cegieska K. L., Opolski G., Wilczyska J., Roik M., Kochman J., Martins D., Goncalves I. M. F. J., Pereira H., Faria H., Calisto J., Matos V., Leitao-Marques A., Costa M., Oliveira H., Mota P., Santos W., Brandao V., Caires F. G., Silva B., Teles F. R. C., Almeida M., Goncalves P., Raposo L., Mourao L., Bernardes L., Pedro P. G., Ferreira R., Conduto R., Quininha J., Patricio L., Cacela D., Goncalves J. M., de Sousa L., Adao M., Carvalho L. H. C., Romeira H., Sousa J. P., Garcia J. M. M., Silva J. C., Magalhaes D., Santos P. R., Mendes S. P. G., Pipa J., Nunes L., Ferreira P., Vinereanu D., Udroiu C., Florescu N., Parvu O., Stoicescu C., Dorobantu M., Balanescu S. M., Niculescu R., Calmac L., Marinescu M., Olinic B. D., Ober M., Homorodean C., Budurea C., Hij A., Anton F., Cluj-Napoca, Ortan F., Suciu C., Ursu M., Baba C., Targu-Mures, Dragulescu S. I., Petrescu L., Slovenski M., Gavrilescu D., Dina C., Mut B., Babic R., Colic M., Topic D., Vilarrasa J. B., Pont M. P., Martorell R. M., Rohlfs I., Moreno R. M., Irurita M., Irurita J., de Gran Canaria L. P., Cervantes C. E., Galvan T., Navarro J., Franco D., Rodriguez I. S., Ramirez V. H., Fernandes-Aviles F., Revilla A., Masson N., Dupertuis V., Kachboura S., Iyisoy A., Erol M. K., Ongen Z., Babalik E., Oskan M., Ozdemir N., Oto A., Aytemir K., Yavuz B., Sahin M., Durna K., Aytekin V., Demiroglu C., Gulbaran M., Aytekin S., Catakoglu A. B., Ozme B., Gemici G., Feray H., Schofield P. M., Kahn S., Clarke S., Millington H., Di Mario C., Dempster D., Henderson R. A., Burton J., Falcon-Lang D., Cardiology, Onuma, Y., Kukreja, N., Ramcharitar, S., Hochadel, M., Gitt, A., Serruys, P., Marco, J., Vahanian, A., Weidinger, F., Wijns, W., Zeymer, U., Silber, S., Seabra-Gomez, R., Eberli, F., Manini, M., Bramley, C., Laforest, V., Taylor, C., Huber, K., Backer, G. D., Sirakova, V., Cerbak, R., Thayssen, P., Aziz, O. A., Tammam, K., Lehto, S., Delahaye, F., Kobulia, B., Cokkinos, D., Kremastinos, D., Karlocai, K., Shelley, E., Behar, S., Maggioni, A., Grabauskiene, V., Deckers, J., Asmussen, I., Stepinska, J., Goncalves, L., Fonseca, C., Mareev, V., Vasilijevic, Z., Riecansky, M. I., Kenda, M. F., Lopez-Sendon, J. L., Rosengren, A., Buser, P., Okay, T., Sychov, O., Schofield, P., Gitt, A. K., Tavazzi, L., Gomes, R. S., de la Iglesia, J. M., Wallentin, L., Kearney, P., Mcgregor, K., Simoons, M. L., Squibb, B. -M., Lilly, E., Margaryan, K., Khachatryan, S., Doerler, J., Stocker, E. -M., Altenberger, I. J., Heigert, M., Pichler, M., Christ, S. G., Glogar, H., Lang, I., Ingerle, S., De Wilde, P., de Marneffe, M., Vrolix, B. M., Dens, J., Lierde, J. V., De Wagter, G. X., Carlier, G. M., Weyne, G. A., Legrand, K. V., Doneux, P., Gach, O., Davin, L., Mievis, L. E., Massart, P. -E., Holvoet, N. G., Giunio, L., Glavas, D., Vukovic, I., Markovic, B., Duplancic, D., Runjic, F., Galic, S. E., Mirat, J., Kala, P., Semenka, J., Hlinomaz, O., Petrikovits, E., Widimsky, B. P., Tousek, P., Varvarovsky, P. I., Cappelen, H., Helqvist, O. S., Kelbaek, H., Jorgensen, E., Engstrom, T., Saunamaki, K., Kastrup, J., Clemmensen, P., Hansen, H., Al Abbadi, M., Razek, H. A., Aboul el Nasr, G., Ragi, H., Ibrihim, B., Zarif, B., el Banhawy, N., Sorour, K., Meguid, M. A., Mahrous, A., Al Khashab, K. A., Ahmed Abd Elmoniem, F., El Emry, M., El Naggar, A., Saad, B. A., Laanmets, P., Voitk, J., Lutter, P., Jarvekulg, S., Jalakas, M., Reinmets, J., Marandi, T., Peeba, M., Serka, T., Syvannne, M., Kaihovirta, E., Korpilahti, H. K., Vaittinen, M. -A., Bassand, J. -P., Espinosa, D. P., Cottin, B. Y., Lhuillier, I., Buffet, P., Lorgis, L., Machecourt, D. J., Bertrand, B., Serrano, D., Bonnet, G. J. -L., Steg, M. P. G., Juliard, J. -M., Farnoud, R., Delarche, P. N., Marco, P. J., Petit, F., Farah, B., Carrie, D., Galinier, M., Puel, J., Cahuzac, J., Roncalli, J., Tauzin, S., Elbaz, M., Schachinger, V., Gitt, F. A., am Rhein Ralf Zahn, L., Fraiture, B., Haetinger, S., Klepzig, N. H., Girth, E., Hauber, A., Firschke, O. C., Widmaier, J., Hofbauer, F., Huttl, S., Sechtem, P. U., Parade, U., Linnartz, S. G., Andrianidis, S., Tsiavou, N., Papaioannou, G., Deliargyris, E., Attikis, M., Alexopoulos, D., Davlouros, P., Tsikaderis, D., Dardas, P., Mezilis, N., Istvan, E., Zoltan, B., Turgeman, Y., Khaled, S., Feldman, A., Jafari, J., Manevich, I., Cafri, C., Ilia, R., Abu-Ful, A., Yaroslavslev, S., Wainstain, J. M., Rosenchtein, G., Sheva, B., Krakover, R., Yakov, B., Halon, D., Gruberg, L., Markiewicz, W., Grenadier, E., Boulos, M., Roguin, A., Kerner, A., Amikam, S., Ben-Tzvi, M., Rezmovitz, J., Mosseri, H. M., Lotan, H., Varshizky, B., Nassar, H., Daninberg, H., Rot, D., Vais, T., Benhorin, J., Keren, A., Medina, A., Huri, Z., Brandis, J. S., Schoenmann, G., Kornowski, N. R., Assali, A., Fuch, S., Hasdai, D., Brosh, D., Sela, O., Teplitski, I., Tikva, P., Eisenberg, O., Banai, S., Finkelstein, A., Hasin, Y., Aboud, M., Nahir, M., Qarwani, D., Diab, G., Meloni, L., Lai, G., Cadeddu, M., Pirisi, R., Bonechi, F., Nassi, F., Nieri, M., Taiti, A., Naldoni, A., Calabro, F., Achilli, F., Maggiolini, S., Piatti, L., Tiberti, G., Addamiano, P., Berti, S., Ravani, M., Palmieri, C., Trianni, G., Cardullo, S., Cioppa, A., Rubino, P., Ambrosini, V., Salemme, L., Sorropago, G., Tesorio, T., Geraci, G., Scalise, F., Mazzeti, S., Auguadro, C., Esposito, G., Canali, G., Caccia, M. E., Ruggieri, C., Benedetta, B., de Cesare, N., De Benedictis, M., Coco, T., Manzotti, S., Fraz, O. S., Marraccini, P., Danesi, A., Ricci, R., Ferraironi, A., Olivieri, E., Chiera, A., Garducci, S., Grasseli, D., Mcfadden, E., Cahill, N., Quinn, M., Crean, P., Caroll, E., Foley, D., O'Connor, S., O'Hanlon, R., Lynch, B., O'Donnell, S., Roy, J., O'Brien, D., Krastina, A., Erglis, A., Lawand, S., Dorniak, W., Klaudel, J., Pawlowski, K., Trenkner, W., Janion, M., Sadowski, M., Janion-Sadowska, A., Skorupa, I., Bystryk, L., Kern, A., Janiak, B., Szelemej, R., Ruzyllo, W., Witkowski, A., Deptuch, T., Maczynska-Mazuruk, R., Budaj, A., Cegieska, K. L., Opolski, G., Wilczyska, J., Roik, M., Kochman, J., Martins, D., Goncalves, I. M. F. J., Pereira, H., Faria, H., Calisto, J., Matos, V., Leitao-Marques, A., Costa, M., Oliveira, H., Mota, P., Santos, W., Brandao, V., Caires, F. G., Silva, B., Teles, F. R. C., Almeida, M., Goncalves, P., Raposo, L., Mourao, L., Bernardes, L., Pedro, P. G., Ferreira, R., Conduto, R., Quininha, J., Patricio, L., Cacela, D., Goncalves, J. M., de Sousa, L., Adao, M., Carvalho, L. H. C., Romeira, H., Sousa, J. P., Garcia, J. M. M., Silva, J. C., Magalhaes, D., Santos, P. R., Mendes, S. P. G., Pipa, J., Nunes, L., Ferreira, P., Vinereanu, D., Udroiu, C., Florescu, N., Parvu, O., Stoicescu, C., Dorobantu, M., Balanescu, S. M., Niculescu, R., Calmac, L., Marinescu, M., Olinic, B. D., Ober, M., Homorodean, C., Budurea, C., Hij, A., Anton, F., Cluj-Napoca, Ortan, F., Suciu, C., Ursu, M., Baba, C., Targu-Mures, Dragulescu, S. I., Petrescu, L., Slovenski, M., Gavrilescu, D., Dina, C., Mut, B., Babic, R., Colic, M., Topic, D., Vilarrasa, J. B., Pont, M. P., Martorell, R. M., Rohlfs, I., Moreno, R. M., Irurita, M., Irurita, J., de Gran Canaria, L. P., Cervantes, C. E., Galvan, T., Navarro, J., Franco, D., Rodriguez, I. S., Ramirez, V. H., Fernandes-Aviles, F., Revilla, A., Masson, N., Dupertuis, V., Kachboura, S., Iyisoy, A., Erol, M. K., Ongen, Z., Babalik, E., Oskan, M., Ozdemir, N., Oto, A., Aytemir, K., Yavuz, B., Sahin, M., Durna, K., Aytekin, V., Demiroglu, C., Gulbaran, M., Aytekin, S., Catakoglu, A. B., Ozme, B., Gemici, G., Feray, H., Schofield, P. M., Kahn, S., Clarke, S., Millington, H., Di Mario, C., Dempster, D., Henderson, R. A., Burton, J., and Falcon-Lang, D.

Subjects
Registrie, Male, medicine.medical_treatment, Angiotensin-Converting Enzyme Inhibitors, Comorbidity, Coronary Artery Disease, Severity of Illness Index, Cardiovascular Disease, Hospital Mortality, Registries, Angioplasty, Balloon, Coronary, Drug-Eluting Stents, Middle Aged, Clopidogrel, Europe, Treatment Outcome, Drug-eluting stent, Cardiovascular Diseases, Practice Guidelines as Topic, Female, Guideline Adherence, Inpatient, Cardiology and Cardiovascular Medicine, Human, medicine.drug, medicine.medical_specialty, Diabetic Angiopathie, Adrenergic beta-Antagonists, Diabetic, SDG 3 - Good Health and Well-being, Internal medicine, Diabetes mellitus, Angioplasty, medicine, Humans, Drug eluting stent, cardiovascular diseases, Risk factor, Aged, European Heart Survey, Inpatients, Clinical Audit, business.industry, Platelet Aggregation Inhibitor, Adrenergic beta-Antagonist, Angiotensin-Converting Enzyme Inhibitor, Guideline, medicine.disease, Surgery, Health Care Survey, Health Care Surveys, Conventional PCI, Hydroxymethylglutaryl-CoA Reductase Inhibitor, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Diabetic Angiopathies, Platelet Aggregation Inhibitors
Abstract

Aims: The objective of the study is to determine the demographics and the in-hospital outcome of diabetic and non-diabetic patients treated with percutaneous coronary interventions (PCI) in Europe, to report the type of equipment and technology used for PCI procedures in diabetics and to clarify whether the treatment of diabetic patients complies with current European Society of Cardiology (ESC) guidelines. Methods and results: A total of 14,458 patients treated with PCI were enrolled from 29 member countries of the ESC between June 2005 and January 2006. Data were collected on patient characteristics and treatment, using new Cardiology Audit and Registration Data standards. In total, 3,603 patients (24.9%) were diabetic. Diabetics were older, more often female and had a higher body mass index than non-diabetics. Diabetics had higher rates of hypercholesterolaemia and hypertension, while current smokers were more frequent in the non-diabetics. Diabetics also had significantly higher rates of previous cardiovascular events. Clopidogrel was administered only in 48.1% of diabetic patients before PCI, while IIb/IIIa inhibitors were 22.9% during PCI. At discharge, there was a major adjustment of treatment with increases in the use of Beta-blocker (80.4%), angiotensin converting enzyme inhibitor (ACEI, 71.3%) and statins (89.8%) compared with on admission (Beta-blocker 60.9%, ACEI 55.0%, statin 63.1%). Inhospital mortality was higher in diabetics (1.8% vs 1.2%) although the in-hospital MACCE rate was not significantly different (3.6% vs 3.0%, p=0.09). Conclusions: Diabetic patients treated with PCI were older with more comorbidity. According to ESC guideline, the under-usage of clopidogrel, GP IIb/IIIa inhibitors should be improved. PCI is now taken as a good opportunity to adjust the use of appropriate medication. © Europa Edition. All rights reserved.

Published
2009
Full Text
View/download PDF

7. Glucose-6-phosphate dehydrogenase deficiency (G6PD) as a risk factor of male neonatal sepsis.

Author

Rostami-Far, Z., Ghadiri, K., Rostami-Far, M., Shaveisi-Zadeh, F., Amiri, A, and Zarif, B. Rahimian

Subjects
GLUCOSE 6-phosphatase, SEPSIS, NEONATAL diseases, PENTOSE phosphate pathway, NEUTROPHILS
Abstract

Introduction. Neonatal sepsis is a disease process, which represents the systemic response of bacteria entering the bloodstream during the first 28 days of life. The prevalence of sepsis is higher in male infants than in females, but the exact cause is unknown. Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme in the pentose phosphate pathway, which leads to the production of NADPH. NADPH is required for the respiratory burst reaction in white blood cells (WBCs) to destroy microorganisms. The purpose of this study was to evaluate the prevalence of G6PD deficiency in neonates with sepsis. Materials and methods. This study was performed on 76 neonates with sepsis and 1214 normal neonates from February 2012 to November 2014 in the west of Iran. The G6PD deficiency status was determined by fluorescent spot test. WBCs number and neutrophils percentages were measured and compared in patients with and without G6PD deficiency. Results. The prevalence of the G6PD deficiency in neonates with sepsis was significantly higher compared to the control group (p=0.03). WBCs number and neutrophils percentages in G6PD deficient patients compared with patients without G6PD deficiency were decreased, but were not statistically significant (p=0.77 and p=0.86 respectively). Conclusions. G6PD deficiency is a risk factor of neonatal sepsis and also a justification for more male involvement in this disease. Therefore, newborn screening for this disorder is recommended. [ABSTRACT FROM AUTHOR]

Published
2016

8. Cohort profile. the ESC-EORP chronic ischemic cardiovascular disease long-term (CICD LT) registry

Author

Komajda, Michel, Cosentino, Francesco, Ferrari, Roberto, Laroche, Cécile, Maggioni, Aldo, Steg, Philippe Gabriel, Tavazzi, Luigi, Kerneis, Mathieu, Valgimigli, Marco, Gale, Chris, P, Chris, P Gale, Branko, Beleslin, Andrzej, Budaj, Ovidiu, Chioncel, Nikolaos, Dagres, Nicolas, Danchin, Jonathan, Emberson, David, Erlinge, Michael, Glikson, Alastair, Gray, Meral, Kayikcioglu, Aldo, P Maggioni, Vivien Klaudia Nagy, Aleksandr, Nedoshivin, Anna-Sonia, Petronio, Jolien, Roos-Hesselink, Lars, Wallentin, Uwe, Zeymer, Michel, Komajda, Francesco, Cosentino, Roberto, Ferrari, Gabriel, Steg, Luigi, Tavazzi, Marco, Valgimigli, Gani, Bajraktari, Pedro, Braga, Vakhtang, Chumburidze, Ana Djordjevic Dikic, Adel El Etriby, Fedele, Francesco, Jean Louis Georges, Artan, Goda, Mathieu, Kerneis, Robert, Klempfner, Peep, Laanmets, Abdallah, Mahdhaoui, Iveta, Mintale, Erkin, Mirrakhimov, Zoran, Olivari, Arman, Postadjian, Harald, Rittger, Luis, Rodriguez-Padial, David, Rott, Carlos, Serrano, Evgeny, Shlyakhto, Rimvydas, Slapikas, Maksym, Sokolov, Volha, Sujayeva, Konstantinos, Tsioufis, Dragos, Vinereanu, Parounak, Zelveian, Tase, M, Koci, J, Kuka, S, Nelaj, E, Goda, A, Simoni, L, Beka, V, Dragoti, J, Karanxha, J, Refatllari, I, Shehu, B, Bileri, A, Luzati, M, Shuperka, E, Gace, A, Shirka, E, Knuti, G, Dado, E, Dibra, L, Gjana, A, Kristo, A, Bica, L, Kabili, S, Pjeci, R, Siqeca, M, Hazarapetyan, L, Drambyan, M, Asatrya, K, Nersesyan, S, Ter-Margaryan, A, Zelveian, P, Gharibyan, H, Hakobyan, Z, Sujayeva, V, Koshlataya, O, Rozumovitch, A, Bychkovskaya, E, Lavrenova, T, Tkacheva, L, Dmitrieva, I, Serrano, C, A Cuoco, M, Favarato, D, Garzillo, C, Goes, M, Lima, E, Pitta, F, Rached, F, Segre, C, Ayres, S, Torres, M, S Hussein, M, Ragy, H, Essam, S, Fadala, H, Hassan, A, Zaghloul, S, Zarif, B, A-E, Elbakery, Nabil, M, W Mohammed Mounir, Radwan, F, Elmenyawy, E, Nafee, W, Sabri, M, A Magdy Moustafa, Helal, A, E Mohamed Abdelrahim, A M, A Elseaidy, Yousef, A, Albert, F, Dasoveanu, M, Demicheli, T, Dutoiu, T, Gorka, H, Laure, C, Range, G, Thuaire, C, Lattuca, B, Cayla, G, Delelo, E, Jouve, B, Khachab, H, Rahal, Y, Lacrimini, M, Chayeb, S, Baron, N, Chavelas, C, Cherif, G, Nay, L, Nistor, M, Vienet-Legue, A, J-B, Azowa, Noichri, Y, Kerneis, M, E Van Belle, Cosenza, A, Delhaye, C, Vincent, F, Gaul, A, Pin, G, Valy, Y, Trouillet, C, Laurencon, V, Couppie, P, J-M, Daessle, F De Poli, Goioran, F, Delarche, N, Livarek, B, L Georges, J, M Ben Aziza, Blicq, E, Charbonnel, C, Convers, R, Gibault-Genty, G, Schiele, F, L Perruche, M, Cador, R, B Lesage, J, J Aroulanda, M, Belle, L, Madiot, H, Chumburidze, V, Kikalishvili, T, Kharchilava, N, Todua, T, Melia, A, Gogoberidze, D, Katsiashvili, T, Lominadze, Z, Chubinidze, T, Brachmann, J, Schnupp, S, Linss, A, Truthan, K, M-A, Ohlow, Rosenthal, A, Ungethüm, K, Rieber, J, Deichstetter, M, Hitzke, E, Rump, S, Tonch, R, Achenbach, S, Gerlach, A, Schlundt, C, Fechner, S, Ücker, C, D Garlichs, C, Petersen, I, Thieme, M, Greiner, R, Kessler, A, Rädlein, M, Edelmann, S, Hofrichter, J, Kirchner-Rückert, V, Klug, A, Papsdorf, E, Waibl, P, Rittger, H, Karg, M, Kuhls, B, Kuhls, S, Eichinger, G, Pohle, K, Paleczny, S, Tsioufis, K, Galanakos, S, Georgiopoulos, G, Panagiotis, T, Peskesis, G, Pylarinou, V, Kanakakis, I, Stamatelopoulos, K, Tourikis, P, Tsoumani, Z, Alexopoulos, D, Bei, I, Davlouros, P, Xanthopoulou, I, Trikas, A, Grigoriou, K, Thomopoulos, T, Foussas, S, Vassaki, M, Athanasiou, K, Dimopoulos, A, Papakonstantinou, N, Patsourakos, N, Ionia, N, Patsilinakos, S, Kintis, K, Tziakas, D, Chalikias, G, Kikas, P, Lantzouraki, A, Karvounis, H, Didagelos, M, Ziakas, A, Sarrafzadegan, N, Khosravi, A, Kermani-Alghoraishi, M, Cinque, A, Fedele, F, Mancone, M, Manzo, D, L De Luca, Figliozzi, S, Tarantini, G, Fraccaro, C, Sinagra, G, Perkan, A, Priolo, L, Ramani, F, Ferrari, R, Campo, G, Biscaglia, S, Cortesi, S, Gallo, F, Pecoraro, A, Spitaleri, G, Tebaldi, M, Tumscitz, C, Lodolini, V, Mosele, E, Indolfi, C, Ambrosio, G, S De Rosa, Canino, G, Critelli, C, Calzolari, D, Zaina, C, F Grisolia, E, Ammendolea, C, Russo, P, Gulizia, M, Bonmassari, R, Battaia, E, Moretti, M, Bajraktari, G, Ibrahimi, P, Ibërhysaj, F, Tishukaj, A, Berisha, G, Percuku, L, Mirrakhimov, E, Kerimkulova, A, Bektasheva, E, Neronova, K, Kaneps, P, Libins, A, Sorokins, N, Stirna, V, Rancane, G, Putne, S, Ivanova, L, Mintale, I, Roze, R, Kalnins, A, Strelnieks, A, Vasiljevs, D, Slapikas, R, Babarskiene, R, Viezelis, M, Brazaitis, G, Orda, P, Petrauskaite, J, Kovaite, E, A Rimkiene, M, Skiauteryte, M, Janion, M, Raszka, D, Szwed, H, Dąbrowski, R, Korczyńska, A, Mączyńska, J, Jaroch, J, Ołpińska, B, Sołtowska, A, Wysokiński, A, Kania, A, Sałacki, A, Zapolski, T, Krzesinski, P, Skrobowski, A, Buczek, K, Golebiewska, K, Kolaszyńska-Tutka, K, Piotrowicz, K, Stanczyk, A, Sobolewski, P, Przybylski, A, Harpula, P, Kurianowicz, R, Wojcik, M, Czarnecka, D, Jankowski, P, Drożdż, T, Pęksa, J, Mendes, M, Brito, J, Freitas, P, V Gama Ribeiro, Braga, P, G Ribeiro, V, Melica, B, G Pires de Morais, Rodrigues, A, Santos, L, Almeida, C, L Pop-Moldovan, A, Darabantiu, D, Lala, R, Mercea, S, Sirbovan, I, Pop, D, Zdrenghea, D, Caloian, B, Comșa, H, Fringu, F, Gurzau, D, Iliesiu, A, Ciobanu, A, Nicolae, C, Parvu, I, Vinereanu, D, A Udroiu, C, G Cotoban, A, Pop, C, Dicu, D, Kozma, G, Matei, C, Mercea, D, Tarusi, M, Burca, M, Bengus, C, Ochean, V, Petrescu, L, Alina-Ramona, N, Crisan, S, Dan, R, Matei, O, Buzas, R, Ciobotaru, G, O Petris, A, I Costache, I, Mitu, O, Tudorancea, I, R Parepa, I, Cojocaru, L, Ionescu, M, Mazilu, L, Rusali, A, I Suceveanu, A, C-J, Sinescu, Axente, L, Dimitriu, I, Samoila, N, Mot, S, Cocoi, M, Iuga, H, Dorobantu, M, Calmac, L, Bataila, V, Cosmin, M, Dragoescu, B, Marinescu, M, Tase, A, Usurelu, C, Dondoi, R, C Tudorica, C, A-M, Vintilă, Ciomag, R, Gurghean, A, Ianula, R, Isacoff, D, Savulescu-Fiedler, I, Spataru, D, V Spătaru, D, Horumbă, M, Mihalcea, R, C-I, Balogh, Bakcsi, F, O-B, Szakacs, Iancu, A, Doroltan, P, Dregoesc, I, Marc, M, Niculina, S, Chernova, A, Kuskaeva, A, Novikova, D, Kirillova, I, Markelova, E, Udachkina, E, Khaisheva, L, Razumovskiy, I, Zakovryashina, I, Chumakova, G, Gritzenko, O, Lomteva, E, Shtyrova, T, Vasileva, L, Gosteva, E, Malukov, D, Pyshnograeva, L, Nedbaykin, A, Iusova, I, Gadgiev, R, Grechova, L, Kazakovtseva, M, Maksimchuk-Kolobova, N, Semenova, Y, Rusina, A, Govorin, A, Mukha, N, Radaeva, E, Vasilenko, P, Zhanataeva, L, Kosmachova, E, Tatarintseva, Z, Tripolskaya, N, Borovkova, N, Tokareva, A, Semenova, A, Spiropulos, N, Ginter, Y, Kovalenko, F, Brodskaia, T, A Nevzorova, V, Golovkin, N, Golofeevskii, S, Shcheglova, E, Aleinik, O, Glushchenko, N, Podbolotova, A, Petrova, M, Harkov, E, Lobanova, A, Tsybulskaya, N, Iakushin, S, Kuzmin, D, Pereverzeva, K, Shevchenko, I, Elistratova, O, Fetisova, E, Galyavich, A, Galeeva, Z, Chepisova, M, Eseva, S, Panov, A, Lokhovinina, N, Boytsov, S, Drapkina, O, Shepel, R, Vasilyev, D, Yavelov, I, Kochergina, A, Sedykh, D, Tavlueva, E, Duplyakov, D, Antimonova, M, Kocharova, K, Libis, R, Lopina, E, Osipova, L, Bukatov, V, Kletkina, A, Plaksin, K, Suyazova, S, Nedogoda, S, Chumachek, E, Ledyaeva, A, Totushev, M, Asadulaeva, G, Tarlovskaya, E, Kozlova, N, V Mazalov, K, Valiculova, F, Merezhanova, A, Efremova, E, Menzorov, M, Shutov, A, Garganeeva, A, Aleksandrenko, V, Kuzheleva, E, Tukish, O, Ryabov, V, Belokopytova, N, Lipnyagova, D, Simakin, N, Ivanov, K, Levashov, S, Karaulovskaya, N, Stepanovic, J, Beleslin, B, Djordjevic-Dikic, A, Giga, V, Boskovic, N, Nedeljkovic, I, Dzelebdzic, S, Arsic, S, Jovanovic, S, Katic, J, Milak, J, Pletikosic, I, Rastovic, M, Vukelic, M, Lazar, Z, J Lukic Petrov, Stankov, S, Djokic, D, Kulic, N, Stojiljkovic, G, Stojkovic, G, Stojsic-Milosavljevic, A, Ilic, A, D Ilic, M, Petrovic, D, A Martínez Cámara, L Rodriguez Padial, P Sánchez-Aguilera Sánchez-Paulete, M Iniesta Manjavacas, A, J Irazusta, F, Merás, P, Rial, V, Cejudo, L, J Fernandez Anguita, M, V Martinez Mateo, Gonzalez-Juanatey, C, S de Dios, Martí, D, C Suarez, R, D Garcia Fuertes, D, Pavlovic, D, Mazuelos, F, J Suárez de Lezo, Marin, F, M Rivera Caravaca, J, A Veliz Martínez, Zhurba, S, Mikitchuk, V, Sokolov, M, and Levchuk, N

Subjects
chronic coronary disease, clinical outcomes, demographics, medications, registry

10. ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation.

Author

Sobhy M, Eletriby A, Ragy H, Kandil H, Saleh MA, Farag N, Guindy R, Bendary A, Nayel AME, Shawky A, Khairy A, Mortada A, Zarif B, Badran H, Khorshid H, Mahmoud K, Said K, Leon K, Abdelsabour M, Tawfik M, Abdelmegid MAF, Koriem M, Loutfi M, Wadie M, Elnoamany M, Sadaka M, Seleem M, Zahran M, Amin OA, Elkaffas S, Ayad S, Kilany WE, Ammar W, Elawady W, Elhammady W, and Abdelhady Y

Abstract

Introduction: The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in regulating blood pressure (BP), with dysregulation of RAAS resulting in hypertension and potentially heart failure (HF), myocardial infarction (MI), cardio-renal syndrome, and stroke. RAAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), have advantages beyond BP control. However, differences between these two drug classes need to be considered when choosing a therapy for preventing cardiovascular events., Methods: A panel of 36 Egyptian cardiologists developed consensus statements on RAAS inhibitors for primary and secondary prevention of cardiovascular outcomes and stroke, using a modified three-step Delphi process., Results: The consensus statements highlight the importance of effective BP control and the role of RAAS blockade for prevention and management of various cardiovascular diseases. ACEis and ARBs differ in their mode of action and, thus, clinical effects. On the basis of available evidence, the consensus group recommended the following: ACEis should be considered as first choice (in preference to ARBs) to reduce the risk of MI, for primary prevention of HF, and for secondary prevention of stroke. ACEis and ARBs show equivalent efficacy for the primary prevention of stroke. Evidence also favors the preferential use of ACEis in patients with type 2 diabetes, for BP control, for the primary prevention of diabetic kidney disease, and to reduce the risk of major cardiovascular and renal outcomes. Treatment with an ACEi should be started within 24 h of ST segment elevation MI (and continued long term) in patients with HF, left ventricular systolic dysfunction, and/or diabetes. Angiotensin receptor/neprilysin inhibitors (ARNIs) are the first choice for patients with HF and reduced ejection fraction, with ACEis being the second choice in this group. ARBs are indicated as alternatives in patients who cannot tolerate ACEis. ACEis may be associated with cough development, but the incidence tends to be overestimated, and the risk can be reduced by use of a lipophilic ACEi or combining the ACEi with a calcium channel blocker., Conclusion: RAAS blockade is an essential component of hypertension therapy; however, the protective effects provided by ACEis are superior to those of ARBs. Therefore, an ACEi is indicated in almost all cases, unless not tolerated., Competing Interests: Declarations. Conflict of Interest: Mohamed Sobhy, Adel Eletriby, Hany Ragy, Hossam Kandil, Mohamed Ayman Saleh, Nabil Farag, Ramez Guindy, Ahmed Bendary, Ahmed Mohamed Elmahmoudy Nayel, Ahmed Shawky, Ayman Khairy, Ayman Mortada, Bassem Zarif, Haitham Badran, Hazem Khorshid, Kareem Mahmoud, Karim Said, Khaled Leon, Mahmoud Abdelsabour, Mazen Tawfik, Mohamed Aboel-Kassem F Abdelmegid, Mohamed Koriem, Mohamed Loutfi, Moheb Wadie, Mohamed Elnoamany, Mohamed Sadaka, Mohamed Seleem, Mohamed Zahran, Osama A. Amin, Sameh Elkaffas, Sherif Ayad, Wael El Kilany, Walid Ammar, Waleed Elawady, Walid Elhammady, and Yasser Abdelhady have nothing to disclose. Ethical Approval: As this study was classified as a consensus development technique and did not involve research on patients or patients’ data, obtaining approval from an ethics committee or internal review board was not necessary. All the clinicians who participated in this study are authors, who willingly served as panelists, agreed with the objectives of the modified Delphi panel study, and actively contributed to manuscript development. Doctors who filled in the Delphi questionnaire received an explanation about the project; they were informed about the intention to publish the results and were asked to complete the Delphi questionnaire if they agreed., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

11. Efficient biosorption of Zn(II), Cd(II), and Pb(II) by Aspergillus brasiliensis in industrial wastewater coupled with electrochemical monitoring via sensor enhanced with modified silver nanoparticles.

Author

Zarei R, Sabokbar A, Rahimian Zarif B, Bayat M, and Haghnazari N

Subjects
Water Pollutants, Chemical, Adsorption, Wastewater chemistry, Lead, Cadmium, Aspergillus metabolism, Zinc, Silver chemistry, Metal Nanoparticles chemistry
Abstract

This work investigates the use of Aspergillus brasiliensis, this particular species of Aspergillus, as a biosorbent for the first time. It is employed to biosorption Zn(II), Cd(II), and Pb(II) and combines the biosorption experiments with electrochemical measurements for in situ analysis. For the experiments, a batch system was employed with the dead biomass. In order to determine the biosorption capacity, the impact of several operational parameters was examined, including pH, temperature, agitation speed, contact time, and initial metal concentration, and the optimum values were 5, 30 °C, 150 rpm, 2 h, and 150 ppm, respectively. Using 0.2 g biomass in 100 mL solution, the maximal uptake of Zn(II), Cd(II), and Pb(II) at ideal conditions was determined to be 33.67, 24.51, and 36.76, respectively. The Langmuir and Freundlich isotherm model was studied for the biosorption process. An electrochemical sensor using nanomaterials is designed and constructed to monitor the concentration of these metals. The silver nanoparticles functionalized with thiosemicarbazide and 6-mercaptohexanoic acid (mercaptohexanoylhydrazinecarbothioamide-coated silver nanoparticles, MHHC-AgNPs) linked to the carboxylated multi-walled carbon nanotubes (MWCNTs) were utilized for glassy carbon electrode modification (MHHC-AgNPs/MWCNTs/GCE). The concentration range of Zn(II) is 0.7-173 µg/L, Cd(II) is 1.18-293 µg/L, and Pb(II) is 2.17-540 µg/L. The detection limits for Zn(II), Cd(II), and Pb(II) are 0.036 µg/L, 0.15 µg/L, and 0.16 µg/L, respectively. Under optimized conditions, these results were obtained using the differential pulse anodic stripping voltammetry method (DPASV). The successful detection of Zn(II), Cd(II), and Pb(II) was achieved by effectively preventing interference from other common ions. It was effectively employed for measuring ions in industrial wastewater, and the results obtained aligned with those acquired from an atomic absorption spectrometer (AAS). Thus, Aspergillus brasiliensis species, along with this electrochemical sensor, can be used to remediate and monitor environmental pollution, Zn(II), Cd(II), and Pb(II), successfully., Competing Interests: Declarations. Ethical approval: Not applicable to this specific section. Consent to participate: All authors whose names appear on this submission, Reza Zarei, Azar Sabokbar, Bahareh Rahimian Zarif, Mansour Bayat, Nahid Haghnazari, and Elahe Ahmadi, 1) made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work 2) drafted the work or revised it critically for important intellectual content 3) approved the version to be published 4) agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved Consent for publication: All authors agreed with the content and that all gave explicit consent to submit and publish. They obtained consent from the responsible authorities at the Islamic Azad University where the work has been carried out. Competing interests: The authors declare no competing interests., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Published
2024
Full Text
View/download PDF

12. Intravascular ultrasound-guided percutaneous coronary intervention for patients with unprotected left main coronary artery lesions.

Author

Bendary A, Elsaed A, Tabl MA, Ahmed ElRabat K, and Zarif B

Subjects
Humans, Coronary Angiography methods, Ultrasonography, Interventional methods, Treatment Outcome, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Artery Disease etiology, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention methods, Drug-Eluting Stents
Abstract

Background: In percutaneous coronary intervention (PCI) procedures for patients with unprotected left main coronary artery (ULMCA) lesions, intravascular ultrasonography (IVUS) guidance has shown potential for enhancing clinical outcomes. However, studies confirming its superiority to conventional angiographic-guided PCI remain few. This study aimed to assess if IVUS-guided PCI for patients with unprotected LMCA stenosis improves clinical outcomes compared to angiographic-guided PCI., Methods: This randomized clinical study enrolled 181 patients with ULMCA lesions scheduled for drug-eluting stent implantation. Patients were split into 90 in the IVUS-guided group and 91 in the conventional group. Procedural characteristics, clinical outcomes, and the incidence of major adverse cardiovascular event (MACE) were evaluated for all patients. The risk reduction associated with IVUS-guided PCI was evaluated using a multivariate Cox regression analysis., Results: Patients who underwent IVUS demonstrated significantly higher pre-dilatation before stenting (88.9% vs. 72.5%, P  = 0.005), post-dilatation balloon diameter (4.46 ± 0.48 vs. 4.21 ± 0.49, P  < 0.001), stent diameter (3.9 ± 0.4 vs. 3.7 ± 0.3, P  = 0.002), and pressure for post dilatation (18 ± 3 vs. 16 ± 2, P  = 0.001). Regarding 12-month outcomes, patients who underwent IVUS demonstrated significantly lower MACE (3.3% vs. 18.7%, P  < 0.001) than those who underwent the conventional method. Multivariate Cox regression analysis revealed that IVUS was related to 84.4% risk reduction of 1-year MACE (HR = 0.156, 95% CI = 0.044-0.556, P  = 0.004)., Conclusion: Compared to angiographic-guided PCI, IVUS-guided PCI resulted in improved clinical results and a markedly reduced risk of MACE in patients with ULMCA lesions., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

13. Proteosomes based on milk phospholipids and proteins to enhance the stability and bioaccessibility of β-carotene.

Author

Zarif B, Shabbir S, Shahid R, Noor T, and Imran M

Subjects
Emulsions chemistry, Whey Proteins chemistry, Caseins chemistry, Milk Proteins chemistry, beta Carotene chemistry, Phospholipids
Abstract

Proteosomes (P) based on milk fat globule membrane's phospholipids (MPs), whey protein isolate (WPI) and sodium caseinate (CasNa) were developed by ultrasonication to encapsulate β-carotene. Entirely milk-ingredients based proteosomes (WPI-MPs-P and CasNa-MPs-P) revealed homogenous distribution with size diameters < 250 nm. WPI-MPs-P depicted positive ζ-potential values (+15.7 ± 0.5 mV), while CasNa-MPs-P demonstrated negative (-32.5 ± 3.4 mV) values of surface charge, respectively and hydrophilic nature of proteosomes was observed by measuring contact-angle (θ). AFM and SEM exhibited spherical to oval and slightly irregular morphology of nanocarriers. For various concentrations of β-carotene, the highest encapsulation efficiency of β-carotene was 90 ± 0.2% and 92 ± 0.8% in WPI-MPs-P and CasNa-MPs-P respectively. FTIR analyses confirmed the hydrophobic and electrostatic interactions-based encapsulation of β-carotene. Beneficial antioxidant-potential of β-carotene was retained after its encapsulation in the proteosomes. Proteosomes increased the digestive-stability (>50%) and bioaccessibility (>85%) of β-carotene. Thus, milk-ingredients based proteosomes offer a novel-strategy to develop functional dairy products to overcome widespread vitamin-A-deficiency., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Ltd. All rights reserved.)

Published
2023
Full Text
View/download PDF

14. Surface engineering of chitosan nanosystems and the impact of functionalized groups on the permeability of model drug across intestinal tissue.

Author

Ejaz S, Ali SMA, Zarif B, Shahid R, Ihsan A, Noor T, and Imran M

Subjects
Rats, Animals, Drug Carriers, Solubility, Permeability, Particle Size, Chitosan, Curcumin pharmacology, Nanoparticles
Abstract

Surface attributes of nanocarriers are crucial to determine their fate in the gastrointestinal (GI) tract. Herein, we have functionalized chitosan with biochemical moieties including rhamnolipid (RL), curcumin (Cur) and mannose (M). FTIR spectra of functionalized chitosan nanocarriers (FCNCs) demonstrated successful conjugation of M, Cur and RL. The functional moieties influenced the entrapment of model drug i.e., coumarin-6 (C6) in FCNCs with payload-hosting and non-leaching behavior i.e., >91 ± 2.5 % with negligible cumulative release of <2 % for 5 h in KREB, which was further verified in the simulated gastric and intestinal fluids. Consequently, substantial difference in the size and zeta potential was observed for FCNCs with different biochemical moieties. Scanning electron microscopy and atomic force microscopy of FCNCs displayed well-dispersed and spherical morphology. In addition, in vitro cytotoxicity results of FCNCs confirmed their hemocompatibility. In the ex-vivo rat intestinal models, FCNCs displayed a time-dependent-phenomenon in cellular-uptake and adherence. However, apparent-permeability-coefficient and flux values were in the order of C6-RL-FCNCs > C6-M-FCNCs > C6-Cur-FCNCs = C6-CNCs > Free-C6. Furthermore, the transepithelial electrical resistance revealed the FCNCs mediated recovery of membrane-integrity with reversible tight junctions opening. Thus, FCNCs have the potential to overcome the poor solubility and/or permeability issues of active pharmaceutical ingredients and transform the impact of functionalized-nanomedicines in the biomedical industry., Competing Interests: Declaration of competing interest The authors declare that there is no conflict of interest regarding the publication of this article., (Copyright © 2023 Elsevier B.V. All rights reserved.)

Published
2023
Full Text
View/download PDF

15. Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial).

Author

Dayem KA, Younis O, Zarif B, Attia S, and AbdelSalam A

Subjects
Humans, Ventricular Function, Left, Stroke Volume, Retrospective Studies, Biomarkers, Natriuretic Peptide, Brain, Peptide Fragments, Myocardial Infarction drug therapy, Anterior Wall Myocardial Infarction, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction drug therapy
Abstract

Background: The role of Sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure is established. Early data also suggests their favorable role in patients with acute coronary syndromes, but more evidence is still needed., Methods: In this dual center, double-blinded randomized controlled trial, non-diabetic patients (N = 100) who presented with anterior ST- elevation myocardial infarction (STEMI) & had undergone successful primary percutaneous coronary intervention, but their left ventricular ejection fraction was below 50%, were randomized to dapagliflozin 10 mg or a placebo once daily. The primary endpoint was a change in cardiac function assessed by N-terminal pro-Brain Natriuretic Peptide - NT-proBNP measured at baseline & 12 weeks post the cardiac event &/or echocardiographic parameters (left ventricular ejection fraction, left ventricular diastolic dimension & left ventricular mass index) assessed at baseline, 4-weeks & 12-weeks post the cardiac event., Results: From October 2021 to April 2022, 100 patients were randomized. The mean drop of NT- proBNP in the study group was more significant compared to the control group by 10.17% (95% CI: -3.28-19.67, p-value 0.034). In addition, the decrease in the left ventricular mass index (LV mass index) was also significant in the study group compared to the control group by 11.46% (95% CI: -19.37 to -3.56, p-value 0.029)., Conclusions: Dapagliflozin seems to have a role in preventing left ventricular dysfunction & maintaining cardiac function following anterior ST-elevation myocardial infarction. More Large-scale trials need to be done to confirm these findings further. This trial is locally registered at the National Heart Institute, Cairo - Egypt, and Faculty of Medicine, Ain Shams University, with reference numbers CTN1012021 & MS-07/2022, respectively. It is also registered retrospectively at the US National Institutes of Health (ClinicalTrial.gov) with identifier number: NCT05424315 - June 16th,2022., Competing Interests: Conflict of interests The authors report no relationships that could be construed as a conflict of interest., (Copyright © 2023 Elsevier B.V. All rights reserved.)

Published
2023
Full Text
View/download PDF

16. Boosting protection for patients with non-acute cardiovascular disease: a focus on antithrombotic regimen (a consensus expert opinion from the Egyptian Society of Cardiology working group of thrombosis and prevention).

Author

Bendary A, Zarif B, Badran HM, Shokry K, and Kabil H

Abstract

Background: Till the moment of this document writing, no Egyptian consensus is there to guide selection of additional antithrombotic in stable patients with established CVD. Despite use of lifestyle measures and statins, those patients with established CVD still face a considerable burden of residual risk., Main Body: With the evolvement of evidence-based medicine, there have been a lot of recommendations to use additional antithrombotic medications to maximize protection for those patients. Accordingly, the Egyptian Society of Cardiology working group of thrombosis and prevention took the responsibility of providing an expert consensus on the current recommendations for using antithrombotic medications to maximize protection in stable patients with established CVD. For stable patients with established CVD, in addition to proper lifestyle measures and appropriate dose statins, we recommend long-term aspirin therapy. In patients who are unable to take aspirin and in those with a history of gastrointestinal bleeding, clopidogrel is a reasonable alternative., Conclusions: For some stable atherosclerotic CVD patients who are at high risk of cardiovascular events and at low risk for bleeding, a regimen of rivaroxaban and aspirin might be taken into consideration., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

17. Characterization of features and outcomes of young patients (< 45 years) presenting with ST-segment elevation myocardial infarction.

Author

Samir A, Almahjori M, Zarif B, Elshinawi M, Yehia H, Elhafy M, Shehata A, and Farrag A

Abstract

Background: Coronary artery disease (CAD) is the commonest cause of death worldwide. ST-segment elevation myocardial infarction (STEMI) and its consequences can be devastating particularly at younger age for a bigger impact on the patient's psychology and ability to work. Little is known about the differential features and outcomes of young STEMI patients in Egypt. This study characterized young STEMI patients (≤ 45 years) compared to patients > 45 years and evaluated 1-year outcomes., Results: A total of 492 eligible STEMI patients who presented to the National Heart Institute and Cairo University Hospitals were recruited. Young STEMI patients (< 45 years old) represented 20% of all STEMI comers. Male gender was predominant in both groups, yet with a significantly higher proportion in the younger compared to older patients (87% vs. 73%, p = 0.004). Compared to older patients, young STEMI patients had characteristically higher rates of smoking (72.4% vs. 49.7%, p < 0.001) and family history (13.3% vs. 4.8%, p = 0.002), while significantly lower rate of other conventional CAD risk factors as diabetes, hypertension, and dyslipidemia (20.4% vs. 44.7%, 20.4% vs. 44.9% and 12.7% vs. 21.8%, respectively, p < 0.05 for all). Follow-up was continued for at least 12 months after the index event. Younger STEMI patients had fewer major adverse cardiovascular events and fewer heart failure hospitalizations compared to the older controls (10.2 vs. 23.9% and 18.4% vs. 34.8%, respectively, p < 0.005 for both), however, 1-year mortality was similar (3.1% vs. 4.1%, p = 0.64)., Conclusions: Younger STEMI patients (≤ 45 years) show peculiar characteristics, with significantly higher rates of smoking and family history of premature CAD, while less prevalence of other conventional CAD risk factors. Overall MACE occurred less in younger STEMI patients; however, the mortality rate was similar to the older controls., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

18. Antimicrobial and anti-biofilm effects of carotenoid pigment extracted from Rhodotorula glutinis strain on food-borne bacteria.

Author

Naisi S, Bayat M, Zahraei Salehi T, Rahimian Zarif B, and Yahyaraeyat R

Abstract

Background and Objectives: Carotenoid pigments are among the most important pigments and have many applications in various food, cosmetics, hygiene industries and biotechnology. These pigments are produced by plants and microorganisms including Rhodotorula spp. This research intended to study the antimicrobial and antibiofilm effects of the carotenoid pigment from Rhodotorula glutinis on food spoilage bacteria ( Staphylococcus aureus and Salmonella Typhimurium)., Materials and Methods: The R. glutinis was isolated from milk samples of cows with mastitis and ITS sequence-based typing was performed on them. After extracting the pigment from R. glutinis , its purity was examined using thin-layer chromatography. Following that, the broth microdilution method was used to evaluate antimicrobial effects of the pigment and MtP assay and subsequently scanning electron microscopy were used to assess the antibiofilm effects. In addition, the sub-MIC effects of the pigment on expression of quorum-sensing (QS) genes in S . Typhimurium isolates ( sdiA and luxS ) and S. aureus isolates ( hld ) were studied. Finally, the degree of toxicity of the pigment was analyzed using the MTT assay., Results: ITS sequence analysis of R. glutinis revealed that the recently separated isolates exhibited strong differences with the strains recorded in NCBI database in genetic structure. The pigment produced by R. glutinis had strong antimicrobial effects and its mean MIC against S. Typhimurium isolates (17.0 μl.ml -1 ) was higher than the mean MIC against the S. aureus isolates (4.1 μl.ml -1 ). Electron microscope images and real-time observations indicated that the sub-MIC values of the pigment suppressed biofilm formation by suppressing expression of QS genes. In addition, the mentioned pigment at high MIC concentrations did not have toxic effects on Vero cells., Conclusion: This research suggests that R. glutinis pigment is effective in destroying the planktonic form of food spoilage bacteria and degrading food spoilage biofilm-forming bacteria. Moreover, considering the low toxicity level of R. glutinis pigment for eukaryotic cells, we can suggest its use as a natural antibacterial preservative in various food materials., (Copyright © 2023 The Authors. Published by Tehran University of Medical Sciences.)

Published
2023
Full Text
View/download PDF

19. The five keys for a successful implementation of a cardiac telerehabilitation: a step-by-step effective digitalization of rehabilitation health services in Egypt.

Author

Atef H, Gaber M, and Zarif B

Abstract

Background: Telerehabilitation enables patients to communicate with physicians through the Internet and may be utilized to evaluate patients' conditions and offer treatment plans. This method became necessary as a result of the COVID-19 pandemic and its influence on face-to-face rehabilitation choices. Many rehabilitation professionals throughout the world have turned to the 'online' approach, relying on smartphone and smartwatch services such as WhatsApp, Facebook, and various mobile applications that comply with the ESC requirements., Main Body: Throughout this editorial, we examine the function of cardiac telerehabilitation in light of the journalistic '5 W,' taking into consideration the rising interest in this topic during the 'COVID era.', Conclusions: Telerehabilitation is the future of rehabilitation, particularly in the COVID age. Additionally, telerehabilitation has proved to be successful in the cardiac profession when compared to face-to-face treatments, implying that this type of rehabilitation may continue after the world is COVID-free, and forecasting that it would be the preferable choice in the future., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

20. Testing P2Y12 platelet inhibitors generics beyond bioequivalence: a parallel single-blinded randomized trial.

Author

Zarif B, Soliman L, Sabry NA, and Said E

Abstract

Cardiovascular diseases are the leading cause of death worldwide. Ticagrelor is an oral antiplatelet drug used in acute coronary syndrome. Although generic drugs are approved for their bioequivalence to the original product, they are not necessarily to be therapeutically equivalent. This study was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers. A loading dose of 180 mg ticagrelor named Brilique® or Ticaloguard® followed by a 90 mg twice daily regimen as maintenance dose was given to 14 and 15 volunteers in Tica and Brili groups, respectively. The platelet aggregation on the ADP agonist was assessed at baseline and repeated 1 h and 3 h after the loading dose, on day 4 (after reaching steady-state), 12 and 24 h after discontinuation of the antiplatelet drug. Adverse effects from trial medications were noted by direct questions. It was shown that generic Ticaloguard® provides a similar therapeutic effect and safety as its branded Brilique® (p > 0.05). This will permit safe and trusted use of the generic Ticaloguard® when treating it in the same manner as Brilique®. Testing generic drug effects rather than simple bioequivalency, especially for drugs that are used in critical life-threatening situations, is crucial. We advocate applying this form of a clinical trial to test surrogate clinical efficacy for generics used in critical indications before having real-world data whenever possible., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

21. Designing an immunosensor for detection of Brucella abortus based on coloured silica nanoparticles.

Author

Shams A and Rahimian Zarif B

Subjects
Antibodies, Immobilized chemistry, Antibodies, Immobilized immunology, Color, Limit of Detection, Linear Models, Biosensing Techniques methods, Brucella abortus isolation & purification, Immunoassay methods, Nanoparticles chemistry, Silicon Dioxide chemistry
Abstract

Brucellosis has always been a threat to the health and economics of societies. We report a new colorimetric immunoassay based on colored silica nanoparticles for detection of Brucella abortus . An immunosensor was designed based on blue-SiNPs and paramagnetic nanoparticles (PMNPs). The synthesized immunosensor was conjugated with a polyclonal antibody against B. abortus , which was activated by 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and N-hydroxysuccinimide (NHS) to form detection and capture probes, respectively. After adding the conjugates to the bacterial suspension, sandwich structure of PMNPs B. abortus -blue-SiNPs was formed and then separated by a magnet. The blue dye was released from the silica structure and its absorbance was measured at 670 nm with a spectrophotometer. Under optimal conditions, results showed a wide dynamic range from 1.5 × 10 3 to 1.5 × 10 8  cfu mL -1 with a detection limit of 450 cfu mL -1 . The specificity of the sensor was confirmed in comparison with 5 other bacteria. Also, during the 120-days period, the complex was stable. The results suggested that it can be used in real samples ( R 2 = .9865). This designed colorimetric immunoassay strategy can be used as an alternative, user-friendly and on-site tool for the rapid detection of Brucella spp. compared to other common methods with high sensitivity and specificity in a short time.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results